Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

On September 1, 2022 Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, reported that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid) (Press release, Bellicum Pharmaceuticals, SEP 1, 2022, View Source [SID1234618870]). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 12, 2022, and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Kura Oncology to Participate in H.C. Wainwright Global Investment Conference

On September 1, 2022 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the H.C. Wainwright 24th Annual Global Investment Conference (Press release, Kura Oncology, SEP 1, 2022, View Source [SID1234618869]). A pre-recorded presentation will be available to view on-demand beginning at 7:00 a.m. ET / 4:00 a.m. PT on September 12, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded presentation will remain accessible for 90 days in the Investors section of Kura’s website at www.kuraoncology.com.

Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer

On September 1, 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, reported the appointment of Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer (CMO) (Press release, Galera Therapeutics, SEP 1, 2022, View Source [SID1234618868]). Dr. Kennedy is a renowned Johns Hopkins-trained surgical oncologist and former Chief of Pancreatic and Hepatobiliary Surgery at Thomas Jefferson University with over 15 years’ experience in clinical development and biopharma leadership. He will succeed Jon T. Holmlund, M.D., who will retire at the end of this year. In the interim, Dr. Kennedy and Dr. Holmlund will work together closely to ensure a smooth and successful transition, with particular focus on the preparation for the Company’s submission of an NDA to the U.S. FDA for avasopasem by the end of 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to welcome Gene to Galera and are immeasurably grateful to Jon for his invaluable leadership and service over the last 10 years," said Mel Sorensen, M.D., Galera’s President and CEO. "We believe Gene’s extensive clinical trial development, regulatory strategy and oncological medical experience will be instrumental in supporting our team’s plan to finalize our NDA submission package for avasopasem by year-end. In addition, as we continue advancing our anti-cancer programs in the clinic, Gene’s proven leadership managing various aspects of a biopharma business and his oncology expertise, including in pancreatic cancer, will help Galera build upon and execute our long-term clinical strategy."

"I am honored to join Galera during this pivotal time in the Company’s history, and I look forward to working with, and gaining insight from, Jon in the coming months," said Eugene P. Kennedy, M.D., F.A.C.S., Galera’s Chief Medical Officer. "I am also eager to collaborate with the entire Galera management team to drive forward our ongoing anti-cancer clinical trials, aim to commercialize avasopasem and lead innovation in the field of radiotherapy treatment for patients with cancer."

Before joining Galera, Dr. Kennedy served as Chief Medical Officer at Innovative Cellular Therapeutics, where he was an integral part of developing the Phase 1 clinical protocol and filing a first-in-human IND for a solid tumor CAR T-cell therapy. Previously, he served as Chief Medical Officer at Lumos Pharma, where he was responsible for clinical development strategy and execution, as well as investor and patient outreach. Prior to Lumos, Dr. Kennedy served as Chief Medical Officer at NewLink Genetics, where he oversaw clinical trials across multiple product candidates and indications. Prior to joining NewLink Genetics, he served as Associate Professor of Surgery at Thomas Jefferson University and held leadership positions as Chief of the Section of Pancreatic and Hepatobiliary Surgery and Co-Director of the Jefferson Pancreas, Biliary, and Related Cancers Center. Dr. Kennedy also has practiced, taught, and held leadership roles at the Johns Hopkins Hospital and Louisiana State University and has authored over 50 peer-reviewed publications. Dr. Kennedy received a bachelor’s degree from the University of Virginia and an M.D. from the Medical College of Virginia.

Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022

On September 1, 2022 Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, reported that it will host a virtual investor event to review clinical data from the Company’s DCC-3116 and vimseltinib programs to be presented at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022 on Sunday, September 11, 2022, from 7:30 AM to 9:30 AM ET / 1:30 PM CEST to 3:30 PM CEST (Press release, Deciphera Pharmaceuticals, SEP 1, 2022, View Source [SID1234618867]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Deciphera’s management team will be joined by the following key opinion leaders at the event:

Anthony W. Tolcher, M.D., CEO, Founder, and Director of Clinical Research at NEXT Oncology
Jean-Yves Blay, M.D., Ph.D., Medical Oncologist, General Director of the Centre Leon Berard, the Comprehensive Cancer Centre of Lyon, France
The event may be accessed by registering at View Source A webcast of the event will be available in the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source The archived webcast will be available on the Company’s website within 24 hours after the event and will be available for 30 days following the event.

ESMO Congress 2022 Presentation Details:

Title: Initial monotherapy results of a phase 1 first‑in‑human study of ULK1/2 inhibitor DCC‑3116 alone and in combination with MAPK pathway inhibition
Presentation Number: 450O
Speaker: Anthony W. Tolcher, M.D.
Session Name: Proffered Paper Session – Developmental Therapeutics
Date: Saturday, September 10, 2022
Time: 11:05 AM to 11:15 AM CEST
Location: Orléans Auditorium

Title: Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase 2 expansion
Presentation Number: 1509P
Speaker: Jean-Yves Blay, M.D., Ph.D.
Session Name: Poster – Sarcoma
Date: Sunday, September 11, 2022
Time: All day; author available 12 PM to 1 PM CEST
Location: Hall 4

Title: Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase 1 update
Presentation Number: 475P
Speaker: Hans Gelderblom, M.D., Ph.D.
Session Name: Poster – Developmental Therapeutics
Date: Monday, September 12, 2022
Time: All day; author available 12 PM to 1 PM CEST
Location: Hall 4

Exact Sciences to participate in September investor conference

On September 1, 2022 Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, reported that company management will participate in the following conference and invited investors to participate by webcast (Press release, Exact Sciences, SEP 1, 2022, View Source [SID1234618866]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird Global Healthcare Conference, New York
Fireside chat on Tuesday, September 13, 2022 at 3:45 p.m. ET
The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.